Who Is a Candidate for Growth Hormone Peptide Therapy? Patient Selection Basics

The question is usually posed as though the therapy has an established indication and the task is to identify who fits it. For growth hormone secretagogues in ageing adults, that premise does not hold. There is a real diagnosis — adult growth hormone deficiency — with defined criteria and a defined treatment, and it is not the condition most people requesting these peptides have.

What follows is the selection framework that the evidence actually supports: who warrants investigation, who does not, who is excluded outright, and what an honest conversation looks like with the large group in between.

The diagnosis that actually exists

Adult growth hormone deficiency is a recognised condition with a specific pathology behind it. It arises from structural or acquired damage to the hypothalamic-pituitary axis: pituitary adenoma or its surgical or radiation treatment, traumatic brain injury, infiltrative or inflammatory disease, Sheehan's syndrome, or childhood-onset deficiency persisting into adulthood.

The diagnostic requirements are strict. A normal IGF-1 does not exclude the diagnosis, which is why provocative testing is mandatory to confirm it, and a low IGF-1 alone does not establish it either. [1] The insulin tolerance test remains the reference standard, with reported sensitivity around 96% and specificity around 92%, though it is contraindicated in coronary artery disease, seizure disorders and older patients. The glucagon stimulation test and the oral macimorelin test are the accepted alternatives. The one situation where provocative testing can be omitted is a patient with three or more pituitary hormone deficiencies and a low IGF-1, where the diagnosis is already established.

The most consequential guidance for this discussion concerns who should not be tested. Where clinical suspicion is low — no hypothalamic-pituitary disease, no surgery or radiation to the region, no head trauma, no childhood-onset deficiency — the recommendation is that the diagnosis should not be pursued and stimulation testing should not be performed. [2]

Testing anyway creates a specific hazard. The glucagon stimulation test's conventional cut-point can over-diagnose deficiency in overweight and glucose-intolerant patients, because peak GH response falls as BMI rises. The population most likely to present to a longevity clinic asking about body composition is precisely the population in whom a false positive is most likely.

The paradox at the centre of this class

Here is the structural problem with secretagogue selection, and it deserves more attention than it receives.

Sermorelin, CJC-1295 and ipamorelin all act upstream, on the pituitary. They require an intact, responsive somatotroph population and functioning receptor signalling to produce any effect at all. A patient whose pituitary has been damaged by surgery, radiation or a mass — that is, a patient with genuine adult GH deficiency — may have little or no capacity to respond. Those patients need growth hormone itself, not a signal telling a damaged gland to produce more.

The converse is where it becomes uncomfortable. A patient with an intact axis who produces a robust GH pulse in response to a secretagogue has demonstrated that their pituitary works. That is evidence against deficiency, not for it.

This is not a theoretical argument. Macimorelin, the orally active ghrelin receptor agonist used as an FDA-approved diagnostic test for adult GH deficiency, acts at the same receptor as ipamorelin. [3] The GH response to a ghrelin-receptor agonist is literally the test for whether the axis is intact. A strong response to ipamorelin is, pharmacologically, the same information as passing a macimorelin test.

So the class sits awkwardly between two groups: those who would benefit from GH but cannot respond to a secretagogue, and those who can respond but by responding have shown they are not deficient. The therapeutic space in between is not obviously empty, but nobody has defined it, and no trial has characterised who occupies it.

What the symptoms usually turn out to be

Fatigue, reduced exercise tolerance, poor recovery, unfavourable body composition and low mood are the presenting complaints. They are also among the least specific symptoms in medicine.

Before any of this is attributed to the GH axis, the differential deserves proper attention: hypothyroidism, hypogonadism, iron deficiency with or without anaemia, obstructive sleep apnoea, depression, vitamin D deficiency, poorly controlled or undiagnosed diabetes, chronic kidney or liver disease, medication effects, alcohol, and simple deconditioning with inadequate protein intake and sleep.

Several of these are common, treatable and considerably more likely than adult GH deficiency in a patient with no pituitary history. Untreated hypothyroidism and hypoadrenalism also need correction before GH axis assessment in any case, as both affect the results.

Treating the GH axis before this work is done risks two failures at once: an intervention unlikely to help, and a missed diagnosis that would have.

Who is clearly not a candidate

Some exclusions are absolute, others are matters of judgement, but all warrant documentation.

Active malignancy is an exclusion, and a history of malignancy warrants specialist input rather than a clinic-level decision. The concern is sustained IGF-1 elevation in a patient who may harbour residual disease.

Active proliferative or severe non-proliferative diabetic retinopathy is a recognised contraindication to GH therapy.

Critical illness is an exclusion, on the basis of trial evidence that high-dose GH increased mortality in critically ill adults.

Untreated hypothyroidism or adrenal insufficiency must be corrected first, both for safety and because they distort assessment.

Pregnancy and benign intracranial hypertension are exclusions. So is age under 18, where growth and epiphyseal considerations put this firmly in paediatric endocrinology.

Poorly controlled diabetes or significant insulin resistance is at minimum a strong relative contraindication, since GH is counter-regulatory to insulin and will worsen glycaemic control.

Two practical exclusions are easy to overlook. A patient who cannot or will not return for monitoring is not a candidate for a therapy requiring IGF-1 and metabolic surveillance. And a patient seeking this for athletic performance is having a different conversation — these agents are prohibited in competitive sport, and that discussion belongs on the table before anything else.

What the evidence shows in the population actually asking

Most people requesting these peptides are not GH deficient. They are ageing, and the GH axis declines with age in everyone. Whether that decline is a deficiency to be corrected or a normal physiological state is the central unresolved question, and the available evidence does not support treating it as the former.

The best synthesis of growth hormone in healthy older adults pooled trials involving 220 participants across roughly 107 patient-years, at a mean treatment duration of about 27 weeks. [4] It found a reduction in fat mass of approximately 2.1 kg and an increase in lean mass of approximately 2.1 kg, greater in men than women, accompanied by increased rates of adverse events — oedema, arthralgia, carpal tunnel symptoms, gynaecomastia and impaired fasting glucose. Functional benefit was not demonstrated. Those were trials of growth hormone itself; the secretagogues have not been tested to this standard in this population at all.

There is a further consideration that rarely appears in promotional material. In humans with congenital growth hormone receptor deficiency, reduced GH signalling is associated with markedly lower incidence of cancer and diabetes. The broader picture is genuinely mixed — some forms of congenital GH deficiency appear to shorten lifespan — but the human genetic evidence does not point in a single direction, and it certainly does not establish that more GH signalling in later life is beneficial. [5]

The Endocrine Society's position is that GHRH analogues and growth hormone secretagogues exist but are not approved for use as anti-ageing agents. [5]

If you proceed anyway

Some clinicians will treat patients who fall outside the diagnostic criteria, and doing so is not automatically indefensible provided the reasoning is explicit. What makes it defensible is the documentation, not the intention.

The consent conversation should state plainly that the patient does not have a diagnosis of GH deficiency, that the therapy is not approved for the purpose being pursued, and that the human evidence for benefit in their situation is absent rather than merely limited. Where ipamorelin or CJC-1295 are involved, the regulatory position needs to be covered honestly too, since neither is currently on the 503A bulks list.

Monitoring should include baseline and periodic IGF-1 interpreted against the age-adjusted reference range rather than driven toward its upper limit, alongside fasting glucose and HbA1c. Fluid retention, joint pain and carpal tunnel symptoms are dose-related signals that the dose is too high, not side effects to push through.

Most usefully, set the trial up to be capable of failing. Define in advance what improvement would look like, in function rather than in sensation or in a single laboratory value, over a defined period, with a stopping point if it does not arrive. An intervention with no predefined endpoint tends to continue indefinitely on the strength of expectation alone.

Reframing the question

"Is this patient a candidate?" presumes a therapy with an established population. The more useful questions are narrower: what specifically am I treating, how would I know whether it worked, what else could explain these symptoms, and what is the cost of being wrong?

For the small number of patients with genuine pituitary pathology, the answers are clear and the treatment is growth hormone under endocrinology care. For the much larger number with non-specific symptoms and an intact axis, the honest answer is that the diagnosis does not fit, the evidence does not exist, and the work most likely to help them is less interesting than a peptide but considerably better supported.

For a comparison of the three compounds themselves, see Growth hormone secretagogues 101. For the receptor biology, see How peptide hormones signal through receptors. For the current compounding position, see Is peptide therapy legal in your state?.